Alarkawi D, Ali MS, Bliuc D, et al. - Using real-world data, researchers explored the connection between oral bisphosphonates (oBPs) and all-cause mortality in individuals with moderate-severe CKD (G3B-5D; ie, eGFR < 45 mL/min/1.73 m²). In this bi-national population-based cohort study, they involved candidates aged 40 years or older with an eGFR < 45 mL/min/1.73 m² at the time of biochemistry testing with at least 1 year of follow-up data available. Findings suggested no association of oBPs with increased mortality among patients with moderate-severe CKD in this observational, patient-based cohort study. Further studies, however, are required on other effects of oBPs in CKD individuals.